Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study-Reference-Cited by-同舟云学术

Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study

Published:2022-10-19 Issue:12 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Ruggiero Angelo¹^ORCID,Potestio Luca¹^ORCID,Cacciapuoti Sara¹,Gallo Lucia¹,Battista Teresa¹,Camela Elisa¹^ORCID,Fabbrocini Gabriella¹^ORCID,Megna Matteo¹^ORCID

Affiliation:

1. Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II Napoli Italy

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15941

Reference12 articles.

1. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

2. Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice

3. Tildrakizumab for the treatment of psoriasis

4. Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting;Burlando M;Drugs Context,2021

5. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience;International Journal of Dermatology;2024-07-12

2. Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation;Expert Opinion on Drug Safety;2024-05-06

3. Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study;Clinical, Cosmetic and Investigational Dermatology;2024-05

4. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials;Clinical, Cosmetic and Investigational Dermatology;2024-04

5. Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study;Drugs in Context;2024-03-18